The primary goal of the Vector Core is to provide participating investigators with the reagents and expertise necessary to utilize various gene delivery systems, both viral and non-viral vectors, in their proposed projects. Broad capabilities must be offered as support to investigative efforts because no single viral vector is completely adequate to satisfy the many technical hurdles which may be encountered in attempting gene therapy for cystic fibrosis. For this reason, the Vector Core will also work closely with projects involved in the development of novel virus- based vectors. Specifically, this Vector Core will provide the following services: l) Consultation to participating investigators who are using specific recombinant systems for gene delivery; 2) Maintenance and distribution of available viral vectors and plasmids with relevant supporting information; 3) Testing and characterization of all vectors provided to investigators for specific research projects; and 4) Providing investigators with all tissue culture and cells required for hybrid virus production. Therefore, the Vector Core is a critical and essential component of the program project and will have a major impact on the success of the various research projects involved. In addition, the centralized service provided by the Vector Core will avoid unnecessary duplication of equipment and supplies, and will also assure better quality control and efficient productivity.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL051818-03
Application #
3737211
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Goudy, Kevin S; Johnson, Mark C; Garland, Alaina et al. (2011) Inducible adeno-associated virus-mediated IL-2 gene therapy prevents autoimmune diabetes. J Immunol 186:3779-86
Li, Wuping; Zhang, Liqun; Wu, Zhijian et al. (2011) AAV-6 mediated efficient transduction of mouse lower airways. Virology 417:327-33
Zhang, Liqun; Collins, Peter L; Lamb, Robert A et al. (2011) Comparison of differing cytopathic effects in human airway epithelium of parainfluenza virus 5 (W3A), parainfluenza virus type 3, and respiratory syncytial virus. Virology 421:67-77
Johnson, Jarrod S; Gentzsch, Martina; Zhang, Liqun et al. (2011) AAV exploits subcellular stress associated with inflammation, endoplasmic reticulum expansion, and misfolded proteins in models of cystic fibrosis. PLoS Pathog 7:e1002053
Johnson, Jarrod S; Li, Chengwen; DiPrimio, Nina et al. (2010) Mutagenesis of adeno-associated virus type 2 capsid protein VP1 uncovers new roles for basic amino acids in trafficking and cell-specific transduction. J Virol 84:8888-902
Kwilas, Anna R; Yednak, Mark A; Zhang, Liqun et al. (2010) Respiratory syncytial virus engineered to express the cystic fibrosis transmembrane conductance regulator corrects the bioelectric phenotype of human cystic fibrosis airway epithelium in vitro. J Virol 84:7770-81
Mitchell, Angela M; Nicolson, Sarah C; Warischalk, Jayme K et al. (2010) AAV's anatomy: roadmap for optimizing vectors for translational success. Curr Gene Ther 10:319-340
Zhang, Liqun; Limberis, Maria P; Thompson, Catherine et al. (2010) ?-Fetoprotein gene delivery to the nasal epithelium of nonhuman primates by human parainfluenza viral vectors. Hum Gene Ther 21:1657-64
Zhang, Liqun; Button, Brian; Gabriel, Sherif E et al. (2009) CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium. PLoS Biol 7:e1000155
Li, Wuping; Zhang, Liqun; Johnson, Jarrod S et al. (2009) Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium. Mol Ther 17:2067-77

Showing the most recent 10 out of 36 publications